In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment right until disease progression or the participants are unable to tolerate the study drugs. Over-all, our existing work highlights the potential utilization of ARV-825 in combination with https://catmano877bmw0.qodsblog.com/profile